RPG Life Sciences AGM: All resolutions passed including ₹24 dividend
RPG Life Sciences Limited's 19th AGM on July 23, 2026, saw all resolutions passed. Key approvals include the FY26 financial statements and a ₹24 per share dividend. Mr. Harsh V. Goenka and Mr. Manoj Maheshwari were re-appointed as directors, and Dr. Pratit Samdani appointed as Independent Director for a five-year term.
The passing of resolutions, especially the dividend declaration and director appointments, has a direct impact on shareholder value and corporate governance, making the impact medium.
The announcement reports the successful passing of all resolutions at the AGM, including the declaration of a dividend and the re-appointment/appointment of directors, which are generally viewed positively by shareholders.
RPG Life Sciences Limited held its Nineteenth Annual General Meeting (AGM) on Thursday, July 23, 2026, commencing at 3:00 p.m. IST via Video Conferencing and other Audio-Visual Means.
During the meeting, all resolutions presented were passed with the requisite majority. Key among the approved items were the adoption of audited standalone and consolidated financial statements for the financial year 2025-26, and the declaration of a dividend of ₹24 (300%) per equity share of ₹8 each for the financial year ended March 31, 2026.
Additionally, the AGM saw the re-appointment of Mr. Harsh V. Goenka and Mr. Manoj Maheshwari as Directors, who retired by rotation. Dr. Pratit Samdani was appointed as an Independent Director for a term of five years, from April 29, 2026, to April 28, 2031. The remuneration payable to the company's Cost Auditors, M/s. Kirit Mehta & Co., for the financial year ending March 31, 2027, was also ratified.
The meeting concluded at 3:38 p.m. IST, with all voting conducted through remote e-voting and an e-voting platform provided by NSDL during the AGM. The proceedings and voting results have been uploaded to the company's website and the NSDL e-voting portal.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.